Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2021

View Archived Issues

Structure-based multivalent nanobodies neutralize SARS-CoV-2 and prevent viral escape

FDA clears IND for phase I trial of MT-6402 in PD-L1-positive solid tumors

FDA accepts C4 Therapeutics' IND for phase I/II trial of CFT-7455 in multiple myeloma and NHL

Gritstone develops second-generation vaccine against SARS-CoV-2

First patient dosed in phase I study of FT-7051 in metastatic CRPC

European Commission approves extension of the indication for Doptelet as treatment of ITP

Preliminary topline phase II data for NSI-566 in ischemic stroke

Positive confirmatory data from atopic dermatitis cohort of EDP-1815 phase Ib trial

Adamis submits IND to the FDA for tempol as treatment of COVID-19

National University of Singapore, Nanyang Technological University patent RNA editing inhibitors

New cannabinoid CB1/CB2 receptor ligands presented by Canopy Growth Corp.

Merck & Co. discovers antituberculosis compounds

Long-term phase III data for lisdexamfetamine dimesylate in preschool-aged children with ADHD

Big picture look reveals RNA-binding proteins' role in psychiatric disorders

Arcutis plans to study roflumilast foam in phase III for seborrheic dermatitis

12-Week study shows benvitimod cream is efficacious and safe in plaque psoriasis

FDA approves IND for phase IIa study of JNJ-40411813 in epilepsy

Inhibitor BAS-2 illuminates role of HDAC6 in glycolytic metabolism in TNBC

c2H2/c3C1, a two-MAb cocktail with high therapeutic efficacy against SARS-CoV-2 infections

Tavotek Biotherapeutics presents bispecific antibodies to TNF-alpha, IL-1beta

Interim phase I data on OTX-TIC in primary open-angle glaucoma or ocular hypertension

MCB-613 attenuates loss of cardiac function after myocardial infarction

Thetis completes pre-IND meeting for TP-317 for inflammatory bowel disease

PK and PD data presented for ADAIR, an IR formulation of dextroamphetamine